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1. Epidemiology
Spinal cord injury (SCI) continues to be a diagnosis without a straightforward
treatment plan, even in today’s advanced medical-technological time. This is a
problematic pathology not only for the patient but also for the health system since,
aside from causing individual disability, it also originates an important economic
cost. This is due—in great part—to the age group most affected by this type of
injury, which regularly involves an average age of injury of 37.1 years old [1].
Spinal cord injury can lead to fatal consequences when autonomic processes such
as respiratory or cardiovascular function are altered by injury. Otherwise, the most
common repercussions are those affecting motor and sensitivity skills. This gener-
ates a scenario where the patient’s clinical prognosis may vary from complete
paralysis to an optimum case of injury where the patient could only need physical
therapy for rehabilitation [2].
The reported prevalence as of 2017 is between 440 and 526 cases per million
population, with a mortality rate as high as 22% in both developed and non-
developed countries [3]. Regarding its incidence, there are 130,000 new cases
reported every year [4]. And even though it may not seem like a large group of
patients, it accounts for more than approximately a million dollars’ worth of treat-
ment for every case reported, thus becoming an important target for research
toward finding an effective treatment that can limit symptomatology as well as
complications due to SCI [3].
SCI pathophysiology encompasses an important number of phenomena that
mainly contribute to SC-tissue destruction and/or regeneration inhibition.
2. Pathophysiology
The understanding of the pathophysiology of acute and chronic SCI is essential
to the development of new therapeutic techniques that can effectively stop damag-
ing mechanisms and promote beneficial effects.
Primary lesion is caused by the physical consequences of injury: contusion,
compression, or laceration [5]. This leads to demyelization and hemorrhage, which
by itself causes ischemia and necrosis affecting nearby cells in the central nervous
system. With this process comes edema which develops hours after the insult and
continues to expand for several days afterward. Finally in this stage, inflammatory
response, cells such as neutrophils and macrophages approach the affected area to
phagocytize the apoptotic and necrotic waste [6].
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After this immediate response to the injury, there is a second phase with further
effects on neural degeneration and tissue restoration:
• Vascular changes. These are due—in great part—to the ischemia that takes
place, especially in the gray matter structures, and are aggravated by the
hypotensive state of hypovolemia. This could be followed by a
reperfusion phase that contributes to a secondary injury and the release of free
radicals [7, 8].
• Oxidative stress. Free radicals have important effects on DNA and proteins by
damaging the cell membrane through lipid peroxidation, as well as promoting
apoptosis, resulting in a strong inhibition of Na-K ATPase [9, 10]. These are
important consequences to keep in mind being that several treatment options
available today such as methylprednisolone are related directly to this
damaging mechanism [6, 11].
• Excitotoxicity. Glutamate, an important neurotransmitter in the central nervous
system, also plays a role in the pathophysiology of SCI, as the extensive release
of this molecule allows calcium entrance and the accumulation of intracellular
Na and Cl (using its NMDA receptor), which in turn results in cytotoxic edema
[12]. Therefore, NMDA receptor blockade becomes a therapeutic option to
further explore.
• Immune response. As an immune-privileged site, the central nervous system is
not known for having a large immune cell presence. Nonetheless, after a SCI,
microglia suffers activation, and cytokines are rapidly released. There is an
increase in the amount of TNF-α and arachidonic acid metabolites that can be
found in cerebral spinal fluid. This, however, is a positive effect since TNF-α
has been shown to increase levels of interleukin-10 which counteracts free
radicals and stimulates axonal regeneration, making it a target for stimulation
as a treatment option [13, 14].
• Activation of Rho pathway. SCI activates Rho pathway, which in turn inhibits
the re-growth of axons and causes apoptosis. By inhibiting this activation,
recovery improves substantially; however, there is no therapy for this purpose
that has been approved yet [15].
• Depletion of cAMP. After injury an important reduction of cAMP in neurons
occurs; this alteration inhibits neuron regeneration [16].
• Glial scar and astrocyte activation. The formation of a glial scar after
injury represents a barrier to growing axons [17–20]. Additionally, activated
astrocytes—the main cells conforming glial scar—express chondroitin
sulfate proteoglycans (CSPGs) and extracellular matrix molecules like
phosphocan and neurocan that, when downregulated, have shown to improve
axonal regeneration, thereby proving their role in regeneration inhibition
[17, 21].
At the moment, there is enough evidence about the deleterious effects exerted
by each one of the abovementioned phenomena. That is why, several investigation
groups are working on developing therapeutic strategies to induce neuroprotection
and subsequently promote SC regeneration.
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3. Neuroprotective therapies
As secondary lesion mechanisms are so abundant and have such a long-term
effect on the patient’s outcome; they have become the main target for SCI therapy.
All of these potential treatment options are involved in various research proposals
as to find suitable possibilities and improve recovery:
• Cyclooxygenase inhibitors. COX is a pro-inflammatory enzyme that leads to the
production of prostanoids and therefore increased inflammation. This is the
basis for the neuroprotective role of cox-inhibitors such as indomethacin
(inhibits COX-1/COX-2 and the activity of select leucocytes, thereby
preventing inflammation aggravation and edema) [22].
• Immunophilin ligands. These proteins are abundantly found in neural tissue and
bind immunosuppressants like cyclosporine A and their analogs which are
known as ligands [23]. When these ligands bind to immunophilins, they inhibit
rotamase and calcineurin activity. These effects decrease immune responses
such as cytokine production and neutrophil motility [24]. Ultimately,
cyclosporine A binding to immunophilin slows down the demyelination
process and stops the spreading of inflammation [25].
• Antioxidants. One of the most damaging pathophysiological mechanisms of SCI
is perhaps the increased release of free radicals [26]. Methylprednisolone,
currently the primary treatment for acute SCI, is aimed toward inhibiting lipid
peroxidation and lactate accumulation. However, there are still concerns about
it being a risk factor for pneumonia development [27].
• Calpain inhibitors. Calpain is a calcium-dependent cysteine protease that
promotes apoptosis through enzyme degradation of cytoskeletal and membrane
proteins. Researchers have found this to be associated with the increased
concentration of intracellular calcium following SCI [28]. The two main classes
include aldehyde-calpain and oxirane inhibitors, of this last one the primary
example is E-64-d. This therapeutic option has demonstrated its neuroprotective
effects in SCI models. By blocking calpains, apoptosis could be reduced [29].
• Apoptosis inhibitors. Caspase-3 and caspase-9 are key mediators for apoptosis
after acute SCI; by inhibiting these molecules, there has been a proven clinical
improvement in previous studies using minocycline. Minocycline is a second-
generation tetracycline that has demonstrated to have anti-inflammatory and
neuroprotective qualities in experimental studies in SCI, stroke, and
neurodegenerative diseases. Talking about its antiapoptotic effects,
minocycline decreases caspase 1 and caspase 3 availability, cytochrome c
release, mitochondrial calcium uptake, and the release of apoptotic factors. By
downsizing apoptosis in SCI, this drug reduces microglial activation [30].
• Hormones. Steroid hormones such as progesterone and estrogen have proven to
be neuroprotective in SCI by showing decreased excitotoxicity, increased
myelination, and enhanced antioxidant properties [31].
• Na channel blockers. Tetrodotoxin is the most investigated compound of this
category; it has proven effects of better recovery by inhibiting fast Na channels
and thereby lessening the continuous depolarized state of injured neurons [32].
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4. Regenerative therapies
• Pharmacological treatments
◦ Rho pathway antagonists. The Rho family has been associated with several
pathways concerning cell proliferation, regeneration, and gene expression
[33]. When activated, it leads to neurite growth blockade, especially when
implicating Rho kinase (ROCK) [34]. This is why Rho-ROCK inhibitors
are now under research as treatment options. These include C3
transferase, which modifies the Rho family thus minimizing its effect, and
Y27632 which competes with ROCK for ATP receptors [35].
◦ Cyclic AMP enhancers. The elevation of cyclic AMP levels is directly
associated with a better neuronal response to myelin inhibitors. This has
led to research for strategies that elevate cyclic AMP, for instance, the
administration of dibutyryl cAMP (activating cAMP-dependent protein
kinase) [36] or the inhibition of phosphodiesterase (PDE) using rolipram
(a PDE-4 inhibitor that targets SNC tissue more specifically) has shown
relevant effects on axonal regeneration [37].
◦ Glial scar inhibitors. Being that the scar itself is an inhibiting factor for
regeneration, several studies have tried to find a strategy to counteract this
effect. Decorin is a proteoglycan molecule that has been linked to a
reduction in the expression of inhibitory molecules such as brevican and
neurocan as well as to the increased capability for axonal growth across
myelin-rich environments [38].
◦ Hydrogels. This type of material allows for healthy tissue to reconnect and
therefore enable axonal growth across the injury. Hydrogels are usually
made of hyaluronic acid or poly(2-hydroxyethyl methacrylate-co-methyl
methacrylate); however, other options are being studied for their
additional benefits. Some of these new prospects include poly(2-
hydroxyethyl methacrylate-co-methyl methacrylate) which has shown
improvement in locomotor function [39] and poly[N-(2-hydroxypropyl)
methacrylamide] with evidence that it has axonogenic and angiogenic
properties [40].
• Scar removal. Numerous research projects have proven that during chronic
stages of injury (>2 weeks), there is a clear benefit when removing the glial scar
given that it portrays a barrier both physically and chemically for axonal
regeneration [21, 41].
• Biocompatible matrices. Tissucol (fibrin glue) is a fibrinogen and thrombin
compound that’s biocompatible and can therefore be used for cell transplant, as
well as promoting growth [42]. Another alternative in this area is alginate, a
biocompatible material obtained from bacteria and algae that promotes cell
migration and axonal growth [43]. Other options in this category include
Matrigel, polyethylene glycol, and hyaluronic acid [44].
• Cell therapies. In chronic stages of SCI, studies have shown that transplanting
different cell types has improved recovery. Mesenchymal stem cells (MSCs)
are the most promising ones so far, with the capacity to modulate the
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microenvironment generated after SCI by secreting anti-inflammatory
molecules and switching from M1 to M2 macrophage phenotype (protective
and restorer phenotype) [45]. They also release neurotrophic factors that
stimulate myelination and reduce apoptosis [46].
• Combination therapies. As there is a large amount of experimental therapies that
target different physiopathological pathways, researchers have found it to be
more effective to combine some of these options when it comes to tackling
acute and chronic injuries [47]. Some examples of this are the combination of
several growth factors and cell transplants, combining chondroitinase ABC and
physical rehabilitation and the surgical removal of scar tissue along with
immune modulatory therapy [48, 49].
So far, there is no definite treatment course for patients with SCI. This fact
remains, although research over the years has developed several options that target
the immunologic response that is triggered after an injury and that have both
beneficial and damaging consequences as well as other mechanisms such as
lipoperoxidation and cytotoxicity. Hence, there are several circumstances that need
to be neutralized before a second strategy can intervene that can initiate remodeling
and restoring the damaged tissue. So far, the understanding of pathophysiological
mechanisms has been our most powerful tool into deciphering the best therapeutic
plan. Neuroprotection is the current target for pharmacological as well as non-
pharmacological therapies such as rolipram, MSCs, methylprednisolone, indometh-
acin, dibutyryl cAMP, and scar removal. The endpoint for all these treatment
options is to encourage and enable neuroregeneration, and although as mentioned
previously, there have been incredible advancements in this area, the search con-
tinues for new alternatives that offer better outcomes.
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